Ignite Creation Date:
2024-05-06 @ 1:49 PM
Last Modification Date:
2024-10-26 @ 1:20 PM
Study NCT ID:
NCT04134923
Status:
RECRUITING
Last Update Posted:
2024-01-17
First Post:
2019-10-18
Brief Title:
Imaging Biomarkers in Preclinical and Symptomatic AD
Sponsor:
Tammie L S Benzinger MD PhD
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Imaging Biomarkers in Preclinical and Symptomatic AD ACS PiB IND
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ACS_PIB_IND
Brief Summary:
The purpose of this research study is to evaluate adult children of parents with and without Alzheimers disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD The investigators will be imaging the brain to detect the presence of amyloid deposits plaques in the brain Amyloid is a protein that may be related to dementia of Alzheimers disease DAT
Detailed Description:
This study will use a radioactive tracer called 11C-Pittsburgh Compound B 11CPIB which is a tracer that binds to beta amyloid protein in the brain This compound is considered investigational which means that it has not been approved by the United States Food and Drug Administration FDA
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None